Skip to content

Study · Randomized controlled trial · n = 2,539 · 2025

5 results

Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.

Mari A, Stefanski A, van Raalte DH, Ma X, LaBell ES, Fan L, Lee CJ, Thomas MK, Bunck MC, Ferrannini E

Diabetes care1 Sept 2025Cited by 5 (Europe PMC)

PMID40694530 (opens in a new tab)PMCIDPMC12368374 (opens in a new tab)DOI10.2337/dc25-0763 (opens in a new tab)PepBankPUB-40694530
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight and prediabetes or normoglycaemia, tirzepatide was associated with body weight reduction at week 72 versus placebo.

    In plain wordsIn adults with overweight or obesity and no diabetes, tirzepatide was linked to weight loss at week 72 compared with placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight reduction at week 72
    Study

    n = 2,539

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 72, tirzepatide treatment was associated with body weight reduction and improvements in insulin sensitivity and β-cell function measures overall and in participants with prediabetes or normoglycemia.
    2 context sentences
    Summary · context
    This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI ≥27 kg/m2 and either prediabetes or normoglycemia at baseline.
    Summary · context
    Model-derived parameters of β-cell function and insulin sensitivity were assessed from oral glucose tolerance tests.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight and prediabetes or normoglycaemia, tirzepatide was associated with improved model-derived insulin sensitivity at week 72 versus placebo.

    In plain wordsIn adults with overweight or obesity and no diabetes, tirzepatide was linked to better insulin sensitivity than placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseInsulin sensitivity at week 72
    Study

    n = 2,539

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 72, tirzepatide treatment was associated with body weight reduction and improvements in insulin sensitivity and β-cell function measures overall and in participants with prediabetes or normoglycemia.
    2 context sentences
    Summary · context
    This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI ≥27 kg/m2 and either prediabetes or normoglycemia at baseline.
    Summary · context
    Model-derived parameters of β-cell function and insulin sensitivity were assessed from oral glucose tolerance tests.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight and prediabetes or normoglycaemia, tirzepatide was associated with improved model-derived beta-cell function at week 72 versus placebo.

    In plain wordsIn adults with overweight or obesity and no diabetes, tirzepatide was linked to better beta-cell function than placebo.

    Peptide
    Tirzepatide
    Outcome
    IncreaseBeta-cell function at week 72
    Study

    n = 2,539

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    At week 72, tirzepatide treatment was associated with body weight reduction and improvements in insulin sensitivity and β-cell function measures overall and in participants with prediabetes or normoglycemia.
    2 context sentences
    Summary · context
    This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI ≥27 kg/m2 and either prediabetes or normoglycemia at baseline.
    Summary · context
    Model-derived parameters of β-cell function and insulin sensitivity were assessed from oral glucose tolerance tests.
  4. 04HumanObservational studyMechanism

    In multivariate models, improved insulin sensitivity on tirzepatide was associated mostly with weight reduction and partly with tirzepatide treatment.

    In plain wordsIn this analysis, better insulin sensitivity on tirzepatide was linked mostly to weight loss and partly to the drug itself.

    Peptide
    Tirzepatide
    Outcome
    Not applicableContributors to improved insulin sensitivity
    Study

    n = 2,539

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    In multivariate regression models, improvements in insulin sensitivity were associated mostly with weight reduction and partly with tirzepatide treatment
    2 context sentences
    Summary · context
    This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI ≥27 kg/m2 and either prediabetes or normoglycemia at baseline.
    Summary · context
    Model-derived parameters of β-cell function and insulin sensitivity were assessed from oral glucose tolerance tests.
  5. 05HumanObservational studyMechanism

    In multivariate models, improved beta-cell function on tirzepatide was associated mostly with tirzepatide treatment.

    In plain wordsIn this analysis, better beta-cell function on tirzepatide was linked mostly to the drug itself rather than to weight loss.

    Peptide
    Tirzepatide
    Outcome
    Not applicableContributors to improved beta-cell function
    Study

    n = 2,539

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    whereas enhancement in β-cell function was mostly associated with tirzepatide treatment.
    2 context sentences
    Summary · context
    This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI ≥27 kg/m2 and either prediabetes or normoglycemia at baseline.
    Summary · context
    Model-derived parameters of β-cell function and insulin sensitivity were assessed from oral glucose tolerance tests.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.